Kyverna Therapeutics, Inc. KYTX Accrued compensation and employee benefits
Accrued compensation and employee benefits at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s accrued compensation and employee benefits.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s accrued compensation and employee benefits?
- Kyverna Therapeutics, Inc. (KYTX) reported accrued compensation and employee benefits of -$6.88M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s accrued compensation and employee benefits changed year-over-year?
- Kyverna Therapeutics, Inc.'s accrued compensation and employee benefits decreased by 281.2% year-over-year, from -$1.8M to -$6.88M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s accrued compensation and employee benefits?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s accrued compensation and employee benefits has grown at a 90.9% compound annual growth rate (CAGR), from $1.4M to $5.11M.